Key Insights From the DEBBRAH and HER2CLIMB-02 Studies

Opinion
Video

Panelists discuss a brief overview of recent data on combination systemic therapies for the treatment of advanced HER2+ breast cancer, including studies such as DESTINY-Breast03, DEBBRAH, HER2CLIMB-02, and EMILIA, and they analyze which patient populations may benefit most from each therapy option based on the available data.

  1. Dr Iyengar: Please provide a brief overview of other recent data in combination systemic therapies for the treatment of advanced RCC. 
    1. DESTINY-Breast03
    2. DEBBRAH
    3. HER2CLIMB-02
    4. EMILIA
  2. Given the available data, for which patient population do you prefer each therapy option and why?
Recent Videos
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
Discussing, Managing, and Treating HER2+ Breast Cancer From the Patient’s Perspective

Discussing, Managing, and Treating HER2+ Breast Cancer From the Patient’s Perspective

ONCOLOGY Staff
December 29th 2024
Article

In a From All Angles program, a patient and her treating physician spoke about the initial diagnosis, care coordination, communication, and the adverse effects observed.